Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteraemia
2018-001207-37Phase 3Active
- Sponsor
- Hospital Universitari
- Start
- Jul 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Staphylococcal bacteremia comparing Cloxacillin + fosfomycin with Cloxacillin monotherapy (2 arms). Primary endpoints: Early treatment success at day 7 and Long-term treatment success. Started Jul 2018; status: active.
02
Drugs
cloxacillinfosfomycin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2018-001207-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001207-37.